Abstract
The antimicrobial activities of amphotericin B, itraconazole, and miconazole against 101 filamentous fungi from patients with cystic fibrosis were tested by a reproducible microdilution method. Itraconazole was very active against Aspergillus species and Scedosporium species (MIC at which 90% of the isolates were inhibited [MIC90], 0.06 to 0.5 mg/liter), whereas amphotericin B was less effective (MIC90, 0.5 to 8 mg/liter).
Full Text
The Full Text of this article is available as a PDF (155.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chung Y., Kraut J. R., Stone A. M., Valaitis J. Disseminated aspergillosis in a patient with cystic fibrosis and allergic bronchopulmonary aspergillosis. Pediatr Pulmonol. 1994 Feb;17(2):131–134. doi: 10.1002/ppul.1950170210. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Tucker R. M., Hanson L. H., Stevens D. A. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989 Jun;86(6 Pt 2):791–800. doi: 10.1016/0002-9343(89)90475-0. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Van Wye J. E., Lewiston N. J., Stevens D. A. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest. 1991 Sep;100(3):813–819. doi: 10.1378/chest.100.3.813. [DOI] [PubMed] [Google Scholar]
- Drent M., van Rens M. T., Wagenaar S. S., de Jongh B. M., van Velzen-Blad H., van den Bosch J. M. Invasive aspergillosis after bilateral lung transplantation in cystic fibrosis. Respir Med. 1995 Jul;89(6):449–451. doi: 10.1016/0954-6111(95)90216-3. [DOI] [PubMed] [Google Scholar]
- Espinel-Ingroff A., Dawson K., Pfaller M., Anaissie E., Breslin B., Dixon D., Fothergill A., Paetznick V., Peter J., Rinaldi M. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 1995 Feb;39(2):314–319. doi: 10.1128/aac.39.2.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gilligan P. H. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev. 1991 Jan;4(1):35–51. doi: 10.1128/cmr.4.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knutsen A., Slavin R. G. Allergic bronchopulmonary mycosis complicating cystic fibrosis. Semin Respir Infect. 1992 Sep;7(3):179–192. [PubMed] [Google Scholar]
- Mannes G. P., van der Heide S., van Aalderen W. M., Gerritsen J. Itraconazole and allergic bronchopulmonary aspergillosis in twin brothers with cystic fibrosis. Lancet. 1993 Feb 20;341(8843):492–492. doi: 10.1016/0140-6736(93)90244-b. [DOI] [PubMed] [Google Scholar]
- Miller M. A., Greenberger P. A., Amerian R., Toogood J. H., Noskin G. A., Roberts M., Patterson R. Allergic bronchopulmonary mycosis caused by Pseudallescheria boydii. Am Rev Respir Dis. 1993 Sep;148(3):810–812. doi: 10.1164/ajrccm/148.3.810. [DOI] [PubMed] [Google Scholar]
- Mroueh S., Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest. 1994 Jan;105(1):32–36. doi: 10.1378/chest.105.1.32. [DOI] [PubMed] [Google Scholar]
- Pfaller M. A., Rex J. H., Rinaldi M. G. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis. 1997 May;24(5):776–784. doi: 10.1093/clinids/24.5.776. [DOI] [PubMed] [Google Scholar]